Pfizer is deepening its investment in protein degraders through a new partnership with Triana Biomedicines, a startup working in the trendy field of molecular glues …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known
Emglev Therapeutics has expertise in the development of therapeutic solutions based on sDAbs. Credit: THICHA SATAPITANON via Shutterstock. Valerio Therapeutics, a developer of DNA Decoy
Mallinckrodt said that it will use the proceeds from the latest deal to reduce net debt by more than 50%. Credit: Ljupco Smokovski via Shutterstock.